Literature DB >> 18849298

Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds.

Roberta Tasso1, Andrea Augello, Michela Carida', Fabio Postiglione, Maria Grazia Tibiletti, Barbara Bernasconi, Simonetta Astigiano, Franco Fais, Mauro Truini, Ranieri Cancedda, Giuseppina Pennesi.   

Abstract

Bone marrow-derived mesenchymal stem cells (MSCs) are precursors of bone, cartilage and fat tissue. MSC can also regulate the immune response. For these properties, they are tested in clinical trials for tissue repair in combination with bioscaffolds or injected as cell suspension for immunosuppressant therapy. Experimental data, however, indicate that MSC can undergo or induce a tumorigenic process in determined circumstances. We used a modified model of ectopic bone formation in mice by subcutaneously implanting porous ceramic seeded with murine MSC. In this new model, host-derived sarcomas developed when we implanted MSC/bioscaffold constructs into syngeneic and immunodeficient recipients, but not in allogeneic hosts or when MSCs were injected as cell suspensions. The bioscaffold provided a tridimensional support for MSC to aggregate, thus producing the stimulus for triggering the process eventually leading to the transformation of surrounding cells and creating a surrogate tumor stroma. The chemical and physical characteristics of the bioscaffold did not affect tumor formation; sarcomas developed either when a stiff porous ceramic was used or when the scaffold was a smooth collagen sponge. The immunoregulatory function of MSC contributed to tumor development. Implanted MSC expanded clones of CD4+CD25+ T regulatory lymphocytes that suppressed host's antitumor immune response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849298     DOI: 10.1093/carcin/bgn234

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  41 in total

Review 1.  Regenerative therapy after cancer: what are the risks?

Authors:  Vera S Donnenberg; Ludovic Zimmerlin; Joseph Peter Rubin; Albert D Donnenberg
Journal:  Tissue Eng Part B Rev       Date:  2010-11-02       Impact factor: 6.389

2.  Tendon stem cells: experimental and clinical perspectives in tendon and tendon-bone junction repair.

Authors:  Pauline Po Yee Lui; On Tik Wong
Journal:  Muscles Ligaments Tendons J       Date:  2012-10-16

Review 3.  Cell-free and cell-based approaches for bone regeneration.

Authors:  Ericka M Bueno; Julie Glowacki
Journal:  Nat Rev Rheumatol       Date:  2009-11-10       Impact factor: 20.543

4.  Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production.

Authors:  Karen McLean; Yusong Gong; Yunjung Choi; Ning Deng; Kun Yang; Shoumei Bai; Lourdes Cabrera; Evan Keller; Laurie McCauley; Kathleen R Cho; Ronald J Buckanovich
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

5.  Hypoxia-mediated efficient expansion of human tendon-derived stem cells in vitro.

Authors:  Wayne Yuk Wai Lee; Pauline Po Yee Lui; Yun Feng Rui
Journal:  Tissue Eng Part A       Date:  2011-10-26       Impact factor: 3.845

Review 6.  Tendon-derived stem cells (TDSCs): from basic science to potential roles in tendon pathology and tissue engineering applications.

Authors:  Pauline Po Yee Lui; Kai Ming Chan
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739

Review 7.  Tissue engineering for the oncologic urinary bladder.

Authors:  Tomasz Drewa; Jan Adamowicz; Arun Sharma
Journal:  Nat Rev Urol       Date:  2012-08-21       Impact factor: 14.432

Review 8.  Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics.

Authors:  Elly De Vlieghere; Laurine Verset; Pieter Demetter; Marc Bracke; Olivier De Wever
Journal:  Virchows Arch       Date:  2015-08-11       Impact factor: 4.064

Review 9.  Mouse models for cancer stem cell research.

Authors:  Le Cheng; Anirudh V Ramesh; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Toxicol Pathol       Date:  2009-11-17       Impact factor: 1.902

Review 10.  Mesenchymal stem cell-based therapy.

Authors:  Vaibhav Mundra; Ivan C Gerling; Ram I Mahato
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.